Merck to start payouts on US Vioxx settlement in August - UPDATE
This article was originally published in Scrip
Executive Summary
Merck & Cosays that more than 97% of eligible claimants in the US have committed to enrol in the proposed $4.85 billion Vioxx (rofecoxib) settlement to resolve Vioxx-related claims in which a claimant suffered a myocardial infarction, sudden cardiac death or stroke.